These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 28643178

  • 1. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
    Panguluri S, Gunda P, Debonnett L, Hamed K.
    Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    McKeage K.
    Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
    [Abstract] [Full Text] [Related]

  • 6. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE.
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
    Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, Murphy DM, Plant BJ.
    J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
    [Abstract] [Full Text] [Related]

  • 10. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
    Meerburg JJ, Andrinopoulou ER, Bos AC, Shin H, van Straten M, Hamed K, Mastoridis P, Tiddens HAWM.
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):61-72. PubMed ID: 32073919
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, Brownlee K.
    Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
    [Abstract] [Full Text] [Related]

  • 12. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F, Carnovale V, Cimino G, Lucidi V, Salvatore D, Messore B, Bartezaghi M, Muscianisi E, Porpiglia PA, FREE study group.
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U, Virella-Lowell I, Angyalosi G, Viegas A, Cao W, Debonnett L.
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [Abstract] [Full Text] [Related]

  • 14. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [Abstract] [Full Text] [Related]

  • 15. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC, Brown R, Sacco P, Zhang J.
    J Med Econ; 2010 Mar; 13(3):492-9. PubMed ID: 20670159
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
    Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A.
    Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
    [Abstract] [Full Text] [Related]

  • 18. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R, Parkins MD.
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [Abstract] [Full Text] [Related]

  • 19. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J.
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.